Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

31
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
31
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

16
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
16
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

30
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
30
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

29
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
29
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

27
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
27
Heart Valves01:16

Heart Valves

5.3K
The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thoracoabdominal aortic replacement in the elderly: a retrospective propensity score-matched outcome analysis.

Annals of medicine and surgery (2012)·2026
Same author

Is Fibrin a Suitable Matrix for Small-Diameter Bioartificial Vascular Grafts? An In Vitro Short-Term Hemocompatibility Study.

Journal of functional biomaterials·2026
Same author

Timing Matters: Impact of Flow and Hypoxia on Capillary Tube Formation in Bioartificial Fibrin-Based Matrices.

Tissue engineering. Part A·2026
Same author

Generation of Fibrin-Based Aortic Vessels with Layer-Specific Cell Architecture Under Pulsatile Perfusion in a Clinical Organ Care System.

Annals of biomedical engineering·2026
Same author

Development and Validation of an Acute Large Animal Model for Type A Aortic Dissection.

Journal of cardiovascular development and disease·2025
Same author

Challenging the Paradigm: Long-Term Outcomes in Dialysis-Dependent Patients Undergoing CABG.

Journal of cardiovascular development and disease·2025

Related Experiment Video

Updated: Aug 8, 2025

Author Spotlight: Advancing Cardiac Procedure Testing Prior to Embarking on Large Animal Studies
06:56

Author Spotlight: Advancing Cardiac Procedure Testing Prior to Embarking on Large Animal Studies

Published on: August 25, 2023

1.0K

A functioning Björk-Shiley aortic valve after 36 years without anticoagulation.

Florian Helms1, Frauke Rosebrock1, Axel Haverich1

  • 1Division of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

Interdisciplinary Cardiovascular and Thoracic Surgery
|March 1, 2023
PubMed
Summary

This case study highlights a Björk-Shiley mechanical aortic valve functioning for 49 years without anticoagulation. This exceptional durability challenges standard anticoagulation guidelines for mechanical heart valves.

Keywords:
AnticoagulationBjörk–ShileyMechanical valve prosthesis

More Related Videos

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.1K
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.4K

Related Experiment Videos

Last Updated: Aug 8, 2025

Author Spotlight: Advancing Cardiac Procedure Testing Prior to Embarking on Large Animal Studies
06:56

Author Spotlight: Advancing Cardiac Procedure Testing Prior to Embarking on Large Animal Studies

Published on: August 25, 2023

1.0K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.1K
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.4K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Mechanical Heart Valves

Background:

  • Clinical guidelines mandate lifelong oral anticoagulation after mechanical heart valve prosthesis implantation.
  • Rare instances of patients not receiving anticoagulation or therapy withdrawal occur.
  • Mechanical heart valves are crucial for managing valvular heart disease.

Purpose of the Study:

  • To report an exceptionally durable mechanical aortic valve prosthesis.
  • To investigate the long-term function of a Björk-Shiley valve in a patient without anticoagulation.
  • To contribute to understanding mechanical valve longevity and management.

Main Methods:

  • Case report of a patient with a Björk-Shiley mechanical aortic valve prosthesis.
  • Review of patient's medical history regarding anticoagulation and antiplatelet therapy.
  • Echocardiographic assessment of prosthetic valve function (gradient and insufficiency).

Main Results:

  • The Björk-Shiley mechanical aortic valve prosthesis functioned for 49 years post-implantation.
  • The patient received no anticoagulation or antiplatelet therapy for the initial 36 years.
  • No thromboembolic or valve-related adverse events were observed.
  • Excellent valve function was confirmed by echocardiography (mean gradient 13 mmHg, no insufficiency).

Conclusions:

  • This case demonstrates exceptional durability of a mechanical aortic valve prosthesis.
  • The findings challenge the absolute necessity of lifelong anticoagulation in all mechanical valve recipients.
  • Further research is warranted to explore factors contributing to such long-term, complication-free mechanical valve function without anticoagulation.